The level of specific IgE and patterns of sensitization to the components of the house dust mite allergen Der p 1 and Der p 2 in children with bronchial asthma

1. Agarkov NM, Ilnitskiy AN, Proshchaev KI, Poshibailova AV, Negrebetskiy VA. The incidence of bronchial asthma in children as an urgent medical and social problem. Healthcare of the Russian Federation. 2019; 63(6): 331–338. (In Russ). https://doi.org/10.18821/0044-197X-2019-63-6-331-338

2. Sánchez-Borges M, Fernandez-Caldas E, Thomas WR, Chapman MD, Lee BW, Caraballo L, Acevedo N, Chew FT, Ansotegui IJ, Behrooz L, Phipatanakul W, Gerth van Wijk R, Pascal D, Rosario N, Ebisawa M, Geller M, Quirce S, Vrtala S, Valenta R, Ollert M, Canonica GW, Calderón MA, Barnes CS, Custovic A, Benjaponpitak S, Capriles-Hulett A. International consensus (ICON) on: clinical consequences of mite hypersensitivity, a global problem. World Allergy Organ J. 2017 Apr 18; 10(1): 14. doi: 10.1186/s40413-017-0145-4.

3. Khokha RN. Sensitization of children with bronchial asthma. Analysis of 10-year dynamics. Journal of Grodno State Medical University. 2019; 17(3): 288–295. (In Russ) http://dx.doi.org/10.25298/2221-8785-2019-17-3-289-295.

4. Wang JY. The innate immune response in house dust mite-induced allergic inflammation. Allergy Asthma Immunol Res. 2013; 5(2): 68–74. doi: 10.4168/aair.2013.5.2.68.

5. Rabe KF, Vermeire PA, Soriano JB, Maier WC. Clinical management of asthma in 1999: the Asthma Insights and Reality in Europe (AIRE) study. Eur. Respir. J. 2000; 16 (5): 802–807. doi: 10.1183/09031936.00.16580200.

6. Peredelskaya MYu, Nenasheva NM. Sublingual immunotherapy with a novel house dust mite allergen: efficacy and safety. Practical allergology. 2021; 2: 20–28. (In Russ). doi:10.46393/2712-9667_2021_2_20_28.

7. Sylvestre L. et al.Component-Based Allergen-Microarray: Der p 2 and Der f 2 Dust Mite Sensitization Is More Common in Patients With Severe Asthma. J Investig Allergol ClinImmunol. 2016; 26(2): 141–143. doi: 10.18176/jiaci.0035.